Ajinomoto Pharmaceuticals Co., Ltd. (“Ajinomoto Pharmaceuticals”) (President, Takashi Nagamachi; Headquarters, Tokyo, Japan) launches today the antihypertensive agent “ATELEC® Tab. 20”, a long-acting calcium channel blocker, indicated for treatment of hypertension. “ATELEC® Tab. 20” was included in the National Health Insurance (NHI) drug price list as of December 13, 2013.

ATELEC® is a long-acting calcium channel blocker that effectively lowers blood pressure by a once-daily dose, and cilnidipine is the active ingredient of ATELEC®. ATELEC® blocks not only L-type but also N-type calcium channels and inhibits blood pressure elevation due to sympathetic nerve hyperactivity as well as suppresses heart rate increase that occurs when blood pressure falls. In a cohort clinical study with patients who have hypertension and also are suffering from chronic kidney disease, ATELEC® has been proven to have kidney protective effects. ATELEC® is available in the Japan market under the brand name of “ATELEC® Tab. 5” and “ATELEC® Tab. 10” distributed by Mochida Pharmaceutical Co., Ltd. (President, Naoyuki Mochida; Headquarters, Tokyo, Japan). “ATELEC® Tab. 20” will be distributed by the same.

In treatment of hypertension, combination use of different agents that have different action mechanisms is common. Patients with hypertension are often required to take a number of tablets in their medication. Ajinomoto Pharmaceuticals expects that ATELEC® Tab. 20 can reduce the number of tablets that patients should take and this will contribute to treatment and increase of patient’s Quality of Life.

Ajinomoto Pharmaceuticals is committed to a healthier and better quality of life of each individual patient through practice of “For Your Quality Of Life” to realize wishes of patients and medical practitioners.
<Indication and dosing regimen of ATELEC®>

<table>
<thead>
<tr>
<th>Brand name</th>
<th>“ATELEC® Tab. 5”, “ATELEC® Tab. 10” and “ATELEC® Tab. 20”</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nonproprietary name</td>
<td>Cilnidipine</td>
</tr>
<tr>
<td>Indication</td>
<td>Hypertension</td>
</tr>
<tr>
<td>Dosing regimen</td>
<td>Normally once daily 5 to 10 mg of cilnidipine after breakfast orally for adult patient. The dose can be increased or reduced according to the age and symptoms. If the above dose is not effective enough, the dose can be increased to 20 mg once daily. For severe hypertension, 10 to 20 mg of cilnidipine orally once daily after breakfast.</td>
</tr>
</tbody>
</table>

“ATELEC® Tab. 20” is an oval tablet with a score line easy for patients to swallow and separate.

【Contact】
Ajinomoto Pharmaceuticals Co., Ltd.
Corporate Planning Dept.
TEL: +81-(0)3-6280-9802
FAX: +81-(0)3-6280-9912

End